tbuckley/cabot-search huggingface dataset:
A randomized pilot study comparing safety and efficacy of irinotecan plus S-1 (IRIS) plus bevacizumab (BV) and modified (m) FOLFIRI plus BV in patients (pts) with metastatic colorectal cancer (mCRC): First report of T-CORE0702.
Authors: S. Kato, H. Andoh, M. Gamoh, T. Yamaguchi, Y. Murakawa, Y. Sasaki, S. Takahashi, H. Shimodaira, T. Yoshioka, C. Ishioka
Journal: Journal of Clinical Oncology (2011)

496 Background: Sequential combination with irinotecan (CPT-11) and S-1 (IRIS) is active and safe regimen against mCRC (ASCO2008, abstract #4107, T. Yoshioka et al. Br J Cancer 101: 1972-77, 2009). The aim of this prospective randomized pilot study was to compare safety (CTCAE v3.0, primary endpoint) and efficacy (RR and PFS, secondary endpoint) of IRIS with mFOLFIRI when these were used with BV. Methods: Sixty pts with mCRC were randomized to compare 30 pts for IRIS+BV (CPT-11 150 mg/m 2 infusion on day 1, S-1 80 mg/m 2 orally on day 3-16, q3w) with 30 pts for mFOLFIRI+BV (CPT-11 150mg/m 2 ). 57 pts (IRIS arm 29, mFOLFIRI arm 28) were evaluable. Most of them were treated as first-line therapy. Results: Background of pts was well balanced among two arms. Although G3/4 hematological AEs profiles were similar between two arms, G2-4 neutropenia was significantly lower in IRIS arm than mFOLFIRI arm (56.6%, vs. 88.9%, p=0.01, χ 2 test). Among G3/4 nonhematological AEs, gastrointestinal toxicities were lower in IRIS arm than mFOLFIRI arm (anorexia: 3.5% vs. 17.9%, nausea: 0% vs. 7.1%, diarrhea: 6.9% vs. 14.3%, stomatitis: 0% vs. 3.6%). By χ 2 test, nausea, vomiting and hair loss were significantly lower in IRIS arm than mFOLFIRI arm (p&lt;0.05). GI-perforation, a BV-related severe AE, occurred in 2 pts only from mFOLFIRI arm and one of them was died as TRD. RRs (institutional evaluation) were 58.6% in IRIS (CR 2, PR 15, SD 11, and PD 1) and 55.1% in mFOLFIRI arm (CR 0, PR 16, SD 10, PD 2, and not evaluable 1). Our independent review committee will clarified definite RR and median PFS near future. Conclusions: Our IRIS+BV regimen is well tolerated, effective and appears to be a promising choice for pts with mCRC. [Table: see text]
Survival benefit with erlotinib-based chemotherapy in unoperable recurrent and/or metastatic pancreatic cancer
Authors: G. F. Samelis, A. Tsiakou, A. Zaganides, K. Ekmektzoglou
Journal: Journal of Clinical Oncology (2008)

15622 Background: Pancreatic cancer represents 2% of all cancers and is the fourth leading cause of cancer-related deaths worldwide. Patients with unresectable and metastatic pancreatic adenocarcinoma had a median survival no longer than 2 months. This is a treatment challenge due to poor outcomes with current treatment modalities. Methods: Chemotherapy naïve patients with histologically confirmed unresectable pancreatic cancer and documented extrapancreatic metastases, received docetaxel 75 mg/m2 on day 1, gemcitabine 1,250 mg/m2 on day 1 and daily erlotinib 100 mg POS, in a biweekly schedule cycle. Patients were monitored every 4 cycles with CT scans and monthly serum CA19–9 measurements. Results: 23 patients (14 male, 9 female, median age 71 years old, range: 41–80, ECOG PS: 0–2) were enrolled, 18 were eligible for the study. 8 patients remain alive and undergoing the study treatment. Patients received on total 146 cycles with a median of 8.33 cycles (range: 2–22). 10 patients discontinued the study, 7 patients terminated due to disease progression and 3 patients due to cumulative asthenia grade III. The grade II hematologic toxicity consisted of: neutropenia in 5 patients (27.7%), anemia in 8 patients (44.4%) and thrombocytopenia in 6 patients (33.3%). 7 patients (38.8%) developed onycholysis grade III-IV and 6 patients (33.3%) developed cumulative fluid retention edema (docetaxel related) that resolved with diuretics and corticosteroids. 10 patients (55.5%) developed skin rush (erlotinib related) grade II toxicity and 9 patients (50%) developed cumulative asthenia after 6 cycles. 1 patient (5.5%) reached CR, 3 patients (16.6%) reached PR and 4 patients (22.2%) showed stabilization in measurable disease. 9 patients (50%) showed amelioration of their pain and their quality of life after a median of 4 cycles of treatment. 9 patients (50%) showed a CA19–9 reduction >50%. The median survival was 5.3 months, range 1–11+. Conclusions: Biweekly chemotherapy with docetaxel, gemcitabine and daily erlotinib is effective for pain control and amelioration of the quality of life in patients with unoperable and/or metastatic pancreatic cancer and offered a median survival of 5.3 months and a reduction >50% in the CA19–9 in 50% of the patients. No significant financial relationships to disclose.
Biallelic inactivation of <i>BRCA2</i> in metastatic castration-resistant prostate cancer and platinum sensitivity.
Authors: Heather H. Cheng, Colin C. Pritchard, Peter Nelson, Robert B. Montgomery
Journal: Journal of Clinical Oncology (2016)

164 Background: Predictive biomarkers are urgently needed in the treatment of metastatic castration-resistant prostate cancer (mCRPC), and the promise of precision medicine depends on understanding the molecular underpinnings of sensitivity to specific therapies. Methods: We identified three patients with mCRPC who achieved exceptional response to platinum chemotherapy after failing prior standard therapies. To identify associated molecular lesions, we retrospectively performed clinical targeted next generation sequencing (UW-OncoPlex) on metastatic and/or primary tumors. Results: Three of three patients were identified to have biallelic inactivation of BRCA2 (breast cancer 2, early onset), a tumor suppressor gene critical for homologous DNA repair and mutations of which are associated with hereditary breast and ovarian cancers. Two patients were subsequently confirmed to carry deleterious germline mutations in BRCA2, including one patient who was diagnosed at age 66 and lacked a significant family history of cancer. The third patient had somatic BRCA2 homozygous copy loss. Conclusions: Biallelic BRCA2 inactivation in mCRPC warrants further study as a predictive biomarker for sensitivity to platinum chemotherapy.
Expression of hepatoma-derived growth factor in early-stage cervical adenocarcinoma
Authors: C. Tsai, M. Tai, T. Hu, S. Huang, J. Lin, H. Chang, C. ChangChien, C. Lai
Journal: Journal of Clinical Oncology (2007)

16002 Background: Hepatoma-derived growth factor (HDGF) is a unique nuclear/growth factor and plays an important role in the progression of different types of cancer. The current study was designed to elucidate the role of HDGF expression during the development of. early-stage cervical adenocarcinoma. Methods: A total of 63 patients with early-stage cervical adenocarcinoma were enrolled in this retrospective study. The HDGF expression in cervical adenocarcinoma was determined by immunohistochemistry. The HDGF immunostaining in the nuclei and cytoplasm of clinical samples was scored and expressed as labeling index to correlate with the clinical parameters of patients with early-stage cervical adenocarcinoma using SPSS software. Results: HDGF immunostaining was detected in both cytoplasm and nucleus of cervical adenocarcinoma. Compared with adjacent non-tumor tissue samples, HDGF expression was significantly increased in either nuclear or cytoplasmic compartment in cervical adenocarcinoma samples (P &lt; 0.001). Moreover, elevated nuclear HDGF levels were correlated with lymph-vascular space invasion (P &lt; 0.05), lymph node metastasis (P &lt; 0.001), recurrence (P &lt; 0.001), advaced grade(P &lt; 0.001). Conclusions: HDGF overexpression is involved in the carcinogenesis of cervical adenocarcinoma. [Table: see text] No significant financial relationships to disclose.
Hematopoietic Stem Cell Transplantation in the Elderly: Nutritional and Geriatric Assessment
Authors: Andrea Z Pereira, Silvia MF Piovacari, Marcia Tanaka, Ana Paula N Barrere, Fabiana Lucio, Juliana Bernardo Silva, Polianna M Goncalves, Ludmila O Koch, Mariana Nicastro, Nelson Hamerschlak
Journal: Blood (2014)
The effectiveness of habit reversal on treatment outcome and quality of life in patients with chronic eczema: a prospective observational study in the U.K.
Authors: T. Tsakok, E. Roberts, C. Bridgett, R.C.D. Staughton
Journal: British Journal of Dermatology (2016)

Our initial observation of the effectiveness of habit reversal for habitual scratching in the treatment of chronic eczema1 led to its introduction at our UK clinic in 1989 2,3, and to the publication of our handbook for practitioners in 1996 4. Between 2005 and 2006, a prospective observational study of 43 successive patients with chronic eczema was conducted to evaluate the effectiveness of habit reversal on disease severity and quality of life for up to 12 months. We recently read with interest the review by Daunton et al 5 on the use of habit reversal in eczema, in which 12 articles are considered - including 4 case reports, 3 case series and 3 RCTs. We note that the largest and most recent of these was in 1995, and included only 30 patients randomised to habit reversal.

This article is protected by copyright. All rights reserved.
P0678 : IL-8 producing CD4+ regulatory T cells stimulate angiogenesis in chronic hepatitis C
Authors: B. Langhans, H.-D. Nischalke, B. Krämer, D.J. Kaczmarek, P. Lutz, C.P. Strassburg, J. Nattermann, U. Spengler
Journal: Journal of Hepatology (2015)
BCRs of Mutated and Unmutated CLL Bind Peptides with Distinct Sequence Features: Evidence from Phage Display Libraries.
Authors: Manuela Woelfle, Till Seiler, Rosa Catera, Hartmut Dohner, Stephan Stilgenbauer, Steven L. Allen, Kanti R. Rai, Charles C. Chu, Nicholas Chiorazzi
Journal: Blood (2007)
Interleukin-6 as a biomarker for asthma: hype or is there something else?
Authors: Matthew E. Poynter, Charles G. Irvin
Journal: European Respiratory Journal (2016)

Much of precision medicine research today seeks to find a biomarker, or like King Richard, our kingdom might be lost. The hope is that if one is successful in identifying such a biomarker [1], all will be resolved: diagnosis, prognosis and the best treatment regime identified from the morass of treatment options available. In this context, the research for a single, do-all biomarker is a truly dramatic irony because it may not exist, consider the rise and fall of C-reactive protein (CRP) or exhaled nitric oxide fraction ( F eNO). Yet such a biomarker could be quite useful in asthma, a syndrome that so often defies definition. With this mythical biomarker, one could clearly decide whether the patient has asthma, assess how severe the disease is, and even guide selection of which of the many available treatment regimens should be employed. Tantalising evidence purports IL-6 to be a biomarker for adult-onset asthma that predicts ICS use and symptoms <http://ow.ly/bhra303fg5j>
Long-term clinical outcome of the patients with nonmetastatic osteosarcoma treated by caffeine-potentiated chemotherapy and function-preserving surgery.
Authors: Hiroyuki Tsuchiya, Norio Yamamoto, Akihiko Takeuchi, Toshiharu Shirai, Katsuhiro Hayashi, Hideji Nishida, Hiroaki Kimura
Journal: Journal of Clinical Oncology (2014)

e21504 Background: Caffeine, a xanthine analogue, inhibits the repair of damaged DNA. Thus, caffeine enhances the cytocidal effects of anticancer drugs. Since 1989, we have utilized caffeine-potentiated chemotherapy in clinical practice for treating high-grade sarcomas. We minimized the surgical margin (intentional marginal margin) for the patients who showed favorable radiological responses to preserve good limb function. The purpose of this study is to evaluate the long-term clinical outcome of the patients with non-metastatic osteosarcoma treated by caffeine-potentiated chemotherapy and function preserving limb-salvage surgery. Methods: The subjects were 57 patients with non-metastatic osteosarcoma. The mean age was 21 years (range: 5-72 years) and the mean follow-up period was 94 months (range 24-222 months). The patients received pre-operatively 3 to 5 courses of intra-arterial infusion of caffeine (1.5g/m2/day x 3days) combined with cisplatinum (120mg/m2/day x 1day) and doxorubicin (30mg/m2/day x 2days). Results: Forty-eight patients (84.2%) were judged as a radiological responder: CR in 31 patients, PR in 17, and NC in 1. Forty-three patients (75.4%) underwent intentional marginal excision, and limb functions of 33 patients (76.7%) were normal as before. In 16 of thirty-nine tumors (41%) around the knee joint, the epiphysis was successfully preserved. Finally, forty-six patients (80.7%) were judged as a histological responder (Rosen & Huvos): Grade IV in 29 patients, III in 17, II in 10, and I in 1. Local recurrence was detected in only 5 patients (8.8%). Out of 9 patients (15.8%) with distant metastasis, 7 were free of disease with a median time of 105 (11-192) months after metastasectomy. The cumulative event-free and disease-specific overall survival rates were 82.6% (5-year), 75.4% (10-year) and 94.2% (5 and 10-year), respectively. Conclusions: Caffeine-potentiated chemotherapy gave rise the excellent radiological and histological responses. Intentional marginal excision for the radiological responders had better clinical courses and it had no adverse impact on the survival rate and local recurrence rate.
Placental growth factor increases regional myocardial blood flow and function in a new porcine model of chronic myocardial ischemia
Authors: Xiaoshun Liu, Ellen Caluwe, Geert Reyns, Peter Verhamme, Peter Pokreisz, Sara Vandenwijngaert, Christophe Dubois, Jarek Zalewski, Stefan Ghysels, Frederik Maes, Hilde Gillijns, Marijke Pellens, Nina Vanden Driessche, Abdulsamie Patel, Frans Van de Werf, Eric Verbeken, Jan Bogaert, Stefan Janssens
Journal: Circulation (2009)
Adult sarcomas: Incidence and initial management before implantation of regional sarcoma committee in northern France.
Authors: K. Ligier, X. Leroy, P. Martin, S. Clisant, F. Richard, N. Penel
Journal: Journal of Clinical Oncology (2010)

e20522 Background: The population-based cancer registry of the Lille Region (Northern France)-780,000 inhabitants covered-had been created in 2005, at the beginning of the French Plan against the Cancer and will allow the measure of the impact of undertaken actions. One of these actions was to promote the multidisciplinary decision making by dedicated regional or inter-regional committee(s). The present analysis is focused on adult sarcomas (AS) and the baseline situation in term of initial management at the beginning of the implementation of (inter-)regional sarcoma committees in 2005. A second work (2011) will analyze the management of the patient after the implementation of sarcoma committees. Methods: We have extracted from the registry all cases of AS recorded in 2005 to check the precise histological diagnosis and the initial treatment. All histological diagnosis have been reviewed. Only adult cases (≥18 years) had been retained. Results: Sixty-two cases were recorded in 2005 by the cancers registry. The crude and standardized (world standard poupulation) incidence rate for AS were respectively 10.3 per 100,000 person-year [95% CI: 7.8-12.9] and 9.9 per 100,000 person-year [95% CI: 7.3-12.4] (cases and person-pear≥ 18 years only).The median age was 57.5 (18-92). The sex ratio M/F was 0.48. The 4 most frequent primary sites were: soft tissue (23), bone (9), uterus (9) and retroperitoneum (6). The 4 most frequent histological types were: liposarcomas (13), mullerian mixte tumours (9), leiomyosarcomas (8) and angiosarcomas (6). There were 3 GIST, 2 Ewing sarcomas and 1 osteosarcoma. Nevertheless, at diagnosis, only 24 cases have been discussed in sarcoma committee (38.7%). This study suggests a higher incidence of sarcoma than expected according to literature data. About a third of cases have been discussed in appropriate committee at diagnosis. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bayer
Decitabine (DAC) Vs. Best Supportive Care in Elderly Patients with Intermediate- and High-Risk MDS with or without Monosomal Karyotypes: Results of the EORTC-LG/German MDS-SG Randomized Phase III Trial 06011.
Authors: Michael Lübbert, Stefan Suciu, Anne Hagemeijer, Ljudmila Bogatyreva, Björn Rüter, Uwe Platzbecker, Aristoteles Giagounidis, Dominik Selleslag, Boris Labar, Ulrich Germing, Helmut R Salih, Liv Meert, Petra Muus, Karl-Heinz Pflüger, Andrea Kuendgen, Carlo Aul, Theo M. de Witte, Arnold Ganser, Jean-Pierre Marie, Pierre W. Wijermans
Journal: Blood (2012)
Outbreak of domestically acquired typhoid fever in Leipzig, Germany, June 2004
Authors: M Muehlen, C Frank, W Rabsch, A Fruth, M Suckau, I Moeller, B Gronemann, R Prager, B R Ruf, T Grünewald, A Ammon, K Stark, K Alpers
Journal: Eurosurveillance (2007)

In June 2004, three confirmed cases of typhoid fever were reported to the health authorities in Leipzig, Germany. The patients had been admitted to hospital with unexplained fever and otherwise mild symptoms. All were members of the same pony club, none had been abroad. A retrospective cohort study among pony club members was performed to identify the source of infection. A suspected case was defined as unexplained fever &amp;gt;=38.5°C over three or more days since 1 May 2004. Additional positive serology defined a probable case and Salmonella Typhi isolation from blood or stool cultures a confirmed case. All hospitals, paediatricians and general practitioners in Leipzig and surroundings were contacted to identify additional cases. In total, six cases were identified, all among pony club members: four confirmed, including the three originally reported cases, one probable and one suspected. The only exposure common to all cases during the probable time of infection was consumption of sandwiches with herb dressing from a snack bar on 25 or 26 May (May 25: RR=5.7; 95% CI 0.9-37.9; both days: RR=, P=0.007). Foods and workers from the snack bar tested negative. However, one worker, not previously registered with the health authorities, was identified during a site visit. It cannot be excluded that further unregistered individuals worked at the snack bar between May and June 2004. Despite intense case-finding activities, no further cases were identified among the population. The most likely vehicle in this outbreak was sandwiches with herb dressing, though the source of contamination remains unknown. Even without history of travel to endemic countries, physicians should consider typhoid fever when managing patients with unexplained fever.
Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study.
Authors: Daniel Richard Gomez, George R. Blumenschein, J. Jack Lee, Mike Hernandez, D. Ross Camidge, Robert Charles Doebele, Laurie E. Gaspar, Don Lynn Gibbons, Jose A. Karam, Brian D. Kavanagh, Ritsuko Komaki, Alexander V. Louie, David A. Palma, Anne S. Tsao, William Nassib William, Jianjun Zhang, Stephen Swisher, John Heymach
Journal: Journal of Clinical Oncology (2016)

9004 Background: We performed a randomized study to assess the effect of aggressive LCT in patients with oligometastatic NSCLC who did not progress after IST. Methods: This study was performed at MD Anderson, U. Colorado, and London HSC, Canada. Eligibility: 1) histologically confirmed NSCLC, 2) Stage IV disease, 3) ≤ 3 metastases, and 4) no RECIST progression after IST. Appropriate IST was defined as either ≥ 4 cycles of platinum doublet therapy or ≥ 3 months of erlotinib/crizotinib for patients with EGFR mutations/ALK fusions, respectively. Patients were randomized to either LCT ([chemo]radiation or surgical resection of all sites) +/- systemic therapy (ST) vs. ST alone. The ST regimen was physician choice from predefined standard-of-care regimens. The primary endpoint was PFS, with the hypothesis that immediate LCT would improve PFS time from 4 months to 7 months (HR = 0.57) using ITT analysis. The planned study size was 94 randomized patients. Randomization was balanced dynamically by number of metastases, IST response, CNS metastases, nodal status, and EGFR/ALK status. Results: Based on the DSMC recommendation, the study was closed early due to significant efficacy benefit observed in the study arm. 49 patients were randomized from 2/2013-1/2016 (25 in LCT arm), 7 of which had EGFR/ALK alterations. At a median follow-up time of 16.2 months, the median PFS time in the LCT arm was 14.4 months (95% CI 5.2 months-NR), compared to 3.9 months (95% CI 2.2-6.6 months) in the no-LCT arm (HR = 0.36, p = 0.013). Seventeen patients in the no-LCT arm crossed over, 14 due to progression. No grade 3-5 toxicity was observed in the LCT group. Of the 28 patients that progressed (12 in LCT, 16 in no-LCT), 7 had progression in the primary site, 3 in a known metastasis, 7 in a different metastasis, and 11 in a combination of sites. The median overall survival time has not yet been reached and patients continue to be followed for this endpoint. Conclusions: In oligometastatic NSCLC patients ( ≤ 3 mets) without progression after IST, immediate LCT +/- ST improved PFS compared to ST alone. Clinical trial information: NCT01725165.
Effect of zoledronic acid combined with cisplatin for non-small cell lung cancer
Authors: Z. Gao, B. Han
Journal: Journal of Clinical Oncology (2008)

19116 Background: Matsumoto et al (Matsumoto, Kimura et al. 2005) investigated the anti-proliferative effects of zoledronic acid (ZA) as a single agent and in combination with other agents against small cell lung cancer cell lines. Walter Berger,et al (Berger, Kubista et al. 2005) investigated whether ZA exerts anticancer activity against human non-small cell lung cancer (NSCLC) cells. ZA treatment resulted in a potent antiproliferative effect against all investigated NSCLC cell lines independent of their Ras and p53 mutation status.Our object is to study the effect and possible mechanism of Zoledronic acid (ZA) combined with cisplatin (DDP) on human non-small cell lung cancer. Methods: The proliferation and apoptosis of human lung cancer cell line A549 were evaluated by MTT reduction assay and flow cytometry respectively. The inhibitory effects of ZA and DDP to neoplasia were verified on subcutaneous implanted tumor of nude mice. Results: Both ZA and DDP could inhibit A549 cell proliferation in a concentration-dependent pattern. When ZA (20μmol/ L) and DDP (>5μmol/ L) were combined, the inhibitory effect was enhanced in a synergistic or additive pattern. Both ZA (20μmol/ L)and DDP(10μmol/ L) could significantly increase the apoptosis of A549 cells ( P<0.05), and this action was remarkably increased when DDP was combined with ZA (P<0.05). ZA and DDP could inhibit the growth of subcutaneous implanted tumor on nude mice and the inhibitory rate of ZA combined with DDP was significantly higher than that of ZA or DDP alone (P<0.05). Conclusions: Zoledronic acid combined with DDP shows significantly synergistic anti-tumor effects on lung cancer cell line A549 and subcutaneous implanted tumor on nude mice, which may be achieved by enhancement of growth inhibition and apoptosis induction to tumor cells. No significant financial relationships to disclose.